|For Healthcare Professional Only|
Clopidogrel - Tablet 75 mg
Clopidogrel is an inhibitor of ptalelet aggregation. A variety of drugs that inhibit platelet function have been shown to decrease morbid events in people with established atherosclerotic cardiovascular disease as evidenced by stroke or transient ischemic attacks, myocardial infarction, or need for bypass or angioplasty. This indicates that platelets participate in the initiation and/or evolution of these events and that inhibiting them can reduce the event rate.
Clopidogrel ls a prodrug. The active metabolite. a thlol derivative. is formed by oxidation of clopidogrel to 2-oxo-clopidogrel and subsequent hydrolysis.
Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation, but an active metabolite responsible for the activity of the drug has not been isolated. Clopidogrel also inhibits platelet aggregation induced by agonists other than ADP by blocking the amplification of platelet activation by released ADR. Clopidogrel does not inhibit phosphodiesterase activity.
Clopidogrel acts by irreversibly modifiying the platelet ADP receptor. Consequently ptatelets exposed to clopidogrel are affected for the remainder ot their lifespan.
Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of clopidogrel. Repeated doses of 75 mg clopidogel per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between day 3 and day 7. At steady state, the average inhibition level observed with a dose of 75 mg clopidogrel per day was between 40% and 60%. Platelet aggregation and bleeding time gractualty return to baseline values after treatment is discontinue, generally in about 5 days.
Effect of food
Administration of clopidogrel with meals did not significantly modify the bioavailability of clopidogrel as assessed by the pharmacokinetics ot the main clrculatlng metabolite.
Absorption and Distribution
Clopidogrel is rapidly absorbed after oral administration of repeated doses 75 mg clopidogrel (base), with peak plasma levels (~3 mg/L) of the main circulating metabolite occuring approximately l hour after dosing. The pharmacokinetics of the main circulating metabolite are linear (plasma concentrations increased in proportion to dose) in the dose range of 50 to l50 mg of clopidogrel. Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites.
Clopidogrel and the main circulating metabolite bind reversibly in vitro to human plasma protein (98% and 94%, respectively). The binding ls nonsaturable in vitro up to a concentration ot l00 µg/mL.
Metabolism and Elimination
in vitro and in vivo, clopidogrel undergoes rapid hydrolysis into its carboxylic acid derivative. In plasma and urine, the glucuronide of the carboxylic acid derivative is also observed.
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerotic documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
The use of clopidogrel is contraindicated in the following conditions:
• Hypersensitivily to the drug substance or any component of the product
• Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Dosage and administration:
The recommended dose ot CLOTIX is 75 mg once daily with or without food.
No dosage adjustment is necessary for elderly patients or patients with renal disease.
• Autonomic nervous system disorders: syncope, palpitation. Body as a whole -general disorders:
asthenia. hernia. Rarely reported (
• Cardiovascular disorders: cardiac failure, edema generalized rarely reported (<1%).
• Central and peripheral nervous system disorders: cramps legs, hypoesthesia, neuralgia, paresthesia, vertigo.
• Gastrointestinal system disorders: constipation, vorniting. Rarely reported (<1%): gastric ulcer perforated,
gastritis hemorrhagic, upper GI ulcer hemorrhagic.
• Heart rate and rhythm disorders: fibrillation atrial.
• Liver and biliary system disorders: hepatic enzymes increased. Rarely reported (<1%): billirubinemia,
hepatitis Infectious, liver fatty.
• Metabolic and nutritional disorders: gout, hyperuricernia, non protein nitrogen [NPN] increased.
• Musculoskeletal system disorders: arthritis, arthrosis.
• Platelet, bleeding and clotting disorders: GI hemorrhage, hematomo, platelets decrease. Rarely
reported (<1%): hemarthrosis, hematuria, hemoptysis, hemorrhage of operative wound, ocular hemorrhage,
pulmonary hemorrhage, purpura allergic, thrombocytopenia.
• Psychiatric dsorders: anxiety insomnia.
• Red blood cell disorders: anemia. Rarely reported (
• Respiratory system disorders: pneumonia, sinusitis. Rarely reported (<1%): hemothorax.
• Skin and appendage disorders: eczema, skin ulceration. Rarely reported (<1%): bullous eruption, rash
erythematous, rash maculopapular, urticaria.
• Urinary system disorders: cystitis.
• Vision disorders: cataract, conjunctivitis.
Other potentially serious adverse events which may be of clinical interest but were rarely reported (
• Reproductive disorders, female: menorrhagia.
• White cell and reticuloendothelial system disorders: agranulocytosis, granulocytopenia, leukemia,
leukopenia, neutrophils decreased.
Warnings and precautions:
• In patients with acute myocardial infarction, clopidogrel therapy should not be initiated within the first few days
following myocardial infarction.
• As with other anti-platelet agents, clopidogrel should be used with caution in patients who may be at risk of
increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment
with ASA, NSAID, heparin, glycoprotein IIb/IIIa inhibitors or thrombolytics.
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during
the first weeks of treatment and/or after invasive cardiac procedures of surgery. If a patient is to undergo
elective surgery and an antiplatelet effect is not desired, clopidogrel should be discontinued 7 days prior to surgery.
• Clapidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a
propensity to bleed (particularly gastrointestinal and intraocular). Patients should be told that it may take longer
than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should
report any unusual bleeding (site or duration) to their physician. Patients should inform physicians and dentists
that they are taking clopidogrel before any surgery is scheduled and before any new drug is taken.
• Therapeutic experience with clopidogrel is limited in patients with renal impairment. Therefore clopidogrel
should be used with caution in these patients.
• Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.
Clopidogrel should therefore be used with caution in this population.
• Due to the risk of bleeding and hematological undesirable effects, blood cell count determination and/or
other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding
arise during the course of treatment.
Pregnancy and lactation:
• Pregnancy: reproduction studies performed in rats and in rabbits revealed no evidence of impaired fertility or
harm to the foetus due to clopidogrel.
There are, however, no adequate and well-controlled studies in pregnant women. In view of the lack of data,
clopidogrel is not recommended during pregnancy.
• Lactation: Studies in rats shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known
whether this medical product is excreted in human milk.
Safety and effectiveness in the patient under T8 years old have not been established.
• The concomitant administration of clopidogrel with warfarin is not recommended since it may increase the
intensity of bleedings.
• Drugs that might induce gastrointestinal lesions (such as Non-Steroidal Anti-Inflammatory Drugs) should be
used with caution in patients taking clopidogrel
• In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin
dose or alter the effect of heparin on coagulation. Co-administration ot heparin had no effect on the inhibition
of platelet aggregation induced by clopidogrel. However the safety of this combination has not been established
and concomitant use should be undertaken with caution.
• The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel.
• Antacids did not modify the extent of clopidogrel absorption.
• Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of
increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein
• Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel mediated inhibition of ADP-induced platelet
aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
• Thrombolytics: the safety of the concomitant administration of clopidogrel, rt-PA and heparin was assessed in
patients with recent myocardial infarction. The incidence of clinically significant bleeding was similar to that
observed when rt-PA and heparin are co-administered with ASA. The safety of the concomitant administration of
clopidogrel with other thrombolytic agents has not been formally established and should undertaken with caution.
For details information, please contact us at firstname.lastname@example.org